In vivo, CXCL4 deletion mitigated hyperoxia-induced lung damage and promoted lung matrix remodeling in neonatal mice with BPD by restoring alveolar architecture and diminishing interstitial fibrosis. This evidence concerns the gene PF4 and bronchopulmonary dysplasia.